CONFERENCE ON MARCH 4, 2013

NEW YORK,  NY -  February 27,  2013  - Delcath  Systems, Inc.  (NASDAQ:  DCTH) 
announced today that Graham  Miao, Ph.D., Executive  Vice President and  Chief 
Financial Officer,  will  present  at  the  Cowen  and  Company  33^rd  Annual 
Healthcare Conference on Monday, March 4, 2013 at 2:50 P.M. ET in Boston,  MA. 
The presentation will include an  overview of the Company's business  strategy 
and recent corporate developments.

A live webcast  and subsequent  archived replay  of the  presentation will  be 
available at  The  presentation 
archived replay will be available  approximately one hour after conclusion  of 
the live event for a period of 90 days.

About Delcath Systems

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company
focused on  oncology.  Our  proprietary drug/device  combination  product  the 
Delcath  Hepatic  Delivery  System  is   designed  to  administer  high   dose 
chemotherapy and other therapeutic agents to diseased organs or regions of the
body, while controlling the systemic  exposure of those agents. The  Company's 
initial focus is on the treatment of primary and metastatic liver cancers.  In 
2010, Delcath  announced  that  its  randomized Phase  3  clinical  trial  for 
patients with metastatic melanoma in  the liver had successfully achieved  the 
study's primary endpoint  of extended hepatic  progression-free survival.  The 
Company also completed a multi-arm Phase 2 trial to treat other liver cancers.
Outside of the United  States, our proprietary product  to deliver and  filter 
melphalan hydrochloride  is  marketed under  the  trade name  Delcath  Hepatic 
CHEMOSAT^® Delivery  System  (CHEMOSAT  Delivery System  for  Melphalan.)  The 
Company obtained  authorization to  affix a  CE Mark  for the  Generation  Two 
CHEMOSAT Delivery System for Melphalan in April 2012. The right to affix  the 
CE mark allows the Company to market and sell the CHEMOSAT Delivery System for
Melphalan in  Europe.  In October  2012,  the  Company satisfied  all  of  the 
requirements to affix  the CE  Mark to  the Hepatic  CHEMOSAT Delivery  System 
device for intra-hepatic  arterial delivery and  extracorporeal filtration  of 
doxorubicin   hydrochloride   injection   (CHEMOSAT   Delivery   System    for 
Doxorubicin), providing a regulatory pathway for the CHEMOSAT Delivery  System 
for Doxorubicin for countries in  Asia that accept the  CE Marking as part  of 
their national regulatory requirements. The Company has not yet received  FDA 
approval for commercial sale of its system in the United States. The Company's
NDA has been accepted for filing and substantive review by the FDA. For  more 
information, please visit the Company's website at

Private Securities Litigation Reform  Act of 1995 provides  a safe harbor  for 
forward-looking statements made  by the Company  or on its  behalf. This  news 
release contains  forward-looking statements,  which  are subject  to  certain 
risks and uncertainties  that can  cause actual results  to differ  materially 
from those described. Factors that may cause such differences include, but are
not limited to, uncertainties  relating to: the outcome  of the ODAC  meeting, 
and the impact, if  any, of the advisory  panel's recommendation on the  FDA's 
decision regarding  the  Company's  new  drug  application  (NDA),  timing  of 
completion of the FDA's  review of our  NDA, the extent to  which the FDA  may 
request additional information or data and our ability to provide the same  in 
a timely manner, acceptability of the Phase 1, 2 and 3 clinical trial data  by 
the FDA,  FDA  approval of  the  Company's NDA  for  the treatment  of  ocular 
metastatic melanoma to the liver, adoption,  use and resulting sales, if  any, 
in the  United States,  adoption, use  and resulting  sales, if  any, for  the 
CHEMOSAT system to  deliver and filter  melphalan in the  EEA, our ability  to 
successfully commercialize the chemosaturation system and the potential of the
chemosaturation system as a treatment for patients with primary and metastatic
disease in the  liver, market acceptance  of the Gen  Two CHEMOSAT system  and 
patient  outcomes  using  the  same,   approval  of  the  current  or   future 
chemosaturation system for delivery  and filtration of melphalan,  doxorubicin 
or other chemotherapeutic agents for various  indications in the US and/or  in 
foreign markets, actions by the FDA or other foreign regulatory agencies,  our 
ability to  successfully enter  into  strategic partnership  and  distribution 
arrangements in foreign markets including Australia and key Asian markets  and 
timing an revenue, if any, of the same, the approval of the Hepatic  CHEMOSAT 
Delivery System device to deliver and filter doxorubicin in key Asian markets
and patient outcomes using the same,  our ability to obtain reimbursement  for 
the CHEMOSAT  system, uncertainties  relating  to the  timing and  results  of 
research and development  projects, uncertainties relating  to the timing  and 
results of future clinical trials, and uncertainties regarding our ability  to 
obtain financial  and  other  resources  for  any  research,  development  and 
commercialization activities. These  factors, and others,  are discussed  from 
time to time in our filings  with the Securities and Exchange Commission.  You 
should not place  undue reliance  on these  forward-looking statements,  which 
speak only  as of  the  date they  are made.  We  undertake no  obligation  to 
publicly update or revise these  forward-looking statements to reflect  events 
or circumstances after the date they are made.

Contact Information:
Investors:                  Financial Media
Gregory Gin/Patty Eisenhaur Chris Gale
EVC Group                  EVC Group
646-445-4801/951-316-0577   646-201-5431


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Delcath Systems, Inc via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.